AIM: To evaluate the premise, that biodegradable polymer drug eluting stents (BD-DES) could improve clinical outcomes compared to second generation permanent polymer drug eluting stents (PP-DES), we pooled the data from all the available randomized control trials (RCT) comparing the clinical performance of both these stents. METHODS: A systematic literature search of PubMed, Cochrane, Google scholar databases, EMBASE, MEDLINE and SCOPUS was performed during time period of January 2001 to April 2015 for RCT and comparing safety and efficacy of BD-DES vs second generation PP-DES. The primary outcomes of interest were definite stent thrombosis, target lesion revascularization, myocardial infarction, cardiac deaths and total deaths during the study period. RESULTS: A total of 11 RCT's with a total of 12644 patients were included in the meta-analysis, with 6598 patients in BD-DES vs 6046 patients in second generation PP-DES. The mean follow up period was 16 mo. Pooled analysis showed non-inferiority of BD-DES, comparing events of stent thrombosis (OR = 1.42, 95%CI: 0.79-2.52, P = 0.24), target lesion revascularization (OR = 0.99, 95%CI: 0.84-1.17, P = 0.92), myocardial infarction (OR = 1.06, 95%CI: 0.86-1.29, P = 0.92), cardiac deaths (OR = 1.07, 95%CI 0.82-1.41, P = 0.94) and total deaths (OR = 0.96, 95%CI: 0.80-1.17, P = 0.71). CONCLUSION: BD-DES, when compared to second generation PP-DES, showed no significant advantage and the outcomes were comparable between both the groups.
AIM: To evaluate the premise, that biodegradable polymer drug eluting stents (BD-DES) could improve clinical outcomes compared to second generation permanent polymer drug eluting stents (PP-DES), we pooled the data from all the available randomized control trials (RCT) comparing the clinical performance of both these stents. METHODS: A systematic literature search of PubMed, Cochrane, Google scholar databases, EMBASE, MEDLINE and SCOPUS was performed during time period of January 2001 to April 2015 for RCT and comparing safety and efficacy of BD-DES vs second generation PP-DES. The primary outcomes of interest were definite stent thrombosis, target lesion revascularization, myocardial infarction, cardiac deaths and total deaths during the study period. RESULTS: A total of 11 RCT's with a total of 12644 patients were included in the meta-analysis, with 6598 patients in BD-DES vs 6046 patients in second generation PP-DES. The mean follow up period was 16 mo. Pooled analysis showed non-inferiority of BD-DES, comparing events of stent thrombosis (OR = 1.42, 95%CI: 0.79-2.52, P = 0.24), target lesion revascularization (OR = 0.99, 95%CI: 0.84-1.17, P = 0.92), myocardial infarction (OR = 1.06, 95%CI: 0.86-1.29, P = 0.92), cardiac deaths (OR = 1.07, 95%CI 0.82-1.41, P = 0.94) and total deaths (OR = 0.96, 95%CI: 0.80-1.17, P = 0.71). CONCLUSION: BD-DES, when compared to second generation PP-DES, showed no significant advantage and the outcomes were comparable between both the groups.
Entities:
Keywords:
Biodegradable drug eluting stent; Cobalt-chromium stent; Drug eluting stent; Stent design; Zotarolimus eluting stent
Authors: Giulio G Stefanini; Robert A Byrne; Patrick W Serruys; Antoinette de Waha; Bernhard Meier; Steffen Massberg; Peter Jüni; Albert Schömig; Stephan Windecker; Adnan Kastrati Journal: Eur Heart J Date: 2012-03-24 Impact factor: 29.983
Authors: Stephan Windecker; Michael Haude; Franz-Josef Neumann; Karl Stangl; Bernhard Witzenbichler; Ton Slagboom; Manel Sabaté; Javier Goicolea; Paul Barragan; Stéphane Cook; Christophe Piot; Gert Richardt; Béla Merkely; Henrik Schneider; Johannes Bilger; Paul Erne; Ron Waksman; Serge Zaugg; Peter Jüni; Thierry Lefèvre Journal: Circ Cardiovasc Interv Date: 2015-02 Impact factor: 6.546
Authors: Ian T Meredith; Stefan Verheye; Christophe L Dubois; Joseph Dens; Jean Fajadet; Didier Carrié; Simon Walsh; Keith G Oldroyd; Olivier Varenne; Seif El-Jack; Raul Moreno; Anita A Joshi; Dominic J Allocco; Keith D Dawkins Journal: J Am Coll Cardiol Date: 2012-02-15 Impact factor: 24.094
Authors: Thomas Pilgrim; Dik Heg; Marco Roffi; David Tüller; Olivier Muller; André Vuilliomenet; Stéphane Cook; Daniel Weilenmann; Christoph Kaiser; Peiman Jamshidi; Therese Fahrni; Aris Moschovitis; Stéphane Noble; Franz R Eberli; Peter Wenaweser; Peter Jüni; Stephan Windecker Journal: Lancet Date: 2014-09-01 Impact factor: 79.321
Authors: Patrick W Serruys; Bernard Chevalier; Dariusz Dudek; Angel Cequier; Didier Carrié; Andres Iniguez; Marcello Dominici; René J van der Schaaf; Michael Haude; Luc Wasungu; Susan Veldhof; Lei Peng; Peter Staehr; Maik J Grundeken; Yuki Ishibashi; Hector M Garcia-Garcia; Yoshinobu Onuma Journal: Lancet Date: 2014-09-14 Impact factor: 79.321
Authors: Stéphane Cook; Elena Ladich; Gaku Nakazawa; Parham Eshtehardi; Michel Neidhart; Rolf Vogel; Mario Togni; Peter Wenaweser; Michael Billinger; Christian Seiler; Steffen Gay; Bernhard Meier; Werner J Pichler; Peter Jüni; Renu Virmani; Stephan Windecker Journal: Circulation Date: 2009-07-20 Impact factor: 29.690
Authors: Pieter Cornelis Smits; Sjoerd Hofma; Mario Togni; Nicolás Vázquez; Mariano Valdés; Vassilis Voudris; Ton Slagboom; Jean-Jaques Goy; Andre Vuillomenet; Antoni Serra; Ramiro Trillo Nouche; Peter den Heijer; Martin van der Ent Journal: Lancet Date: 2013-01-30 Impact factor: 79.321
Authors: Stefan K James; Ulf Stenestrand; Johan Lindbäck; Jörg Carlsson; Fredrik Scherstén; Tage Nilsson; Lars Wallentin; Bo Lagerqvist Journal: N Engl J Med Date: 2009-05-07 Impact factor: 91.245